Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Efavirenz (Sustiva/Strocrin)
 
Journal Citations: Adult/
Adolescent Treatment

General; Reports
 Quality of Life
CNS Benefits
 Efficacy
 Switching Therapy
 Salvage Therapy
 Treatment Strategies
 Drug Failure
 Drug Comparison Studies
 
Efavirenz Main Page Main New/Newsworthy Home Page      
Last Update:  November 04, 2008
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
           
 
A WEEK IN REVIEW FEATURED REPORT
Efavirenz – Still First-line King?
 Best BM, Goicoechea M. 
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):965-972.
 Abstract
 
Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection:
case repor tand review of the literature.
 Torno MS, Witt MD, Saitoh A, Fletcher CV.  
Pharmacotherapy. 2008 Jun;28(6):782-7.
 Abstract
 
Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive
Patients: The Role of Gender.
 Smith CJ, Sabin CA, Youle MS, et al 
J Acquir Immune Defic Syndr. 2007 Jul 19;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efavirenz.
 Maggiolo F
Expert Opin Pharmacother. 2007 Jun;8(8):1137-45.
 Abstract

Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women)
in West Africa.
 Danel C, Moh R, Anzian A, Abo Y, et al   
J Acquir Immune Defic Syndr. 2006 May;42(1):29-35.
Abstract
Quality of Life Studies
           
  Quality of Life, Emotional Status, and Adherence of HIV-1–Infected Patients Treated With Efavirenz.
Fumaz CR, Tuldra A, Ferrer MJ, et al.  
 J Acquir Immune Defic Syndr 2002 Mar1;29(3):244-53
Abstract
Central Nervous System Benefits
 
  Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous
system in HIV-1-infected patients.
von Giesen HJ, Koller H, Theisen A, Arendt G.
J Acquir Immune Defic Syndr 2002 Apr 1;29(4):363-7
 Abstract		  
Efficacy
General Studies                    HIV/TB

General  HIV Studies

 
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes
in Southern African adults.
 Nachega JB, Hislop M, Dowdy DW, et al   
AIDS. 2008 Oct 18;22(16):2117-25.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA
levels and CD4 cell counts.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al
J Infect Dis. 2008 Apr 1;197(7):1006-10
 Abstract
 
Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast).
 Tanon AK, Eholié SP, Polneau S, et a
Med Mal Infect. 2008 Apr 3
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside
analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
 Domingo P, Suárez-Lozano I, Torres F, et al
J Antimicrob Chemother. 2008 Mar 20
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase
inhibitors for HIV-1 infection.
 Tashima K, Staszewski S, Nelson M, et al
AIDS. 2008 Jan 11;22(2):275-279.
Abstract
 
Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with
and without Food, as Initial Therapy for HIV Infection: The ELADI Study.
 Sánchez-Conde M, Palacios R, Sanz J, et al
AIDS Res Hum Retroviruses. 2007 Oct;23(10):1237-1241.
 Abstract
 
Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination
with efavirenz: results of a systematic overview.
Bartlett JA, Chen SS, Quinn JB. 
HIV Clin Trials. 2007 Jul-Aug;8(4):221-6.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination
with efavirenz: results of a systematic overview.
 Bartlett JA, Chen SS, Quinn JB. 
HIV Clin Trials. 2007 Jul-Aug;8(4):221-6.
 Abstract
 
Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or
efavirenz at a university-based outpatient service in Brazil.
 Vanni T, Morejón KM, Santana RC, et al 
Braz J Med Biol Res. 2007 Jul;40(7):963-9.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving either Triple-Nucleoside
or Efavirenz-Containing Regimens: ACTG A5166s
 Kuritzkes DR, Ribaudo HJ, Squires KE, et al
J Infect Dis. 2007 Apr 15;195(8):1169-76.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line
therapy for all?
 Goicoechea M, Best B.
Expert Opin Pharmacother. 2007 Feb;8(3):371-82
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a
Background Therapy Regimen of 2 Nucleoside Reverse-Transcriptase Inhibitors in Patients with
Initially Suppressed Viral Loads.
 Cozzi-Lepri A, Luca AD, Phillips AN, et al 
J Infect Dis. 2006 Jul 1;194(1):20-8.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or
lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
 Panagopoulos P, Tsiodras S, Antoniadou A, et al
Clin Microbiol Infect. 2006 May;12(5):486-9.
 Abstract
 
Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
 Harmann M, Witte S, Brust J, et al
Int J STD AIDS. 2005 Jun;16(6):404-9
Abstract
 
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of
nevirapine or efavirenz-based first-line HAART.
 van Leth F, Andrews S, Grinsztejn B, Wilkins E
 AIDS. 2005 Mar 25;19(5):463-471
 Abstract
 
Plasma HIV-1 RNA Decline Within the First Two Weeks of Treatment Is Comparable
for Nevirapine, Efavirenz, or Both Drugs Combined and Is Not Predictive of Long-Term
Virologic Efficacy: A 2NN Substudy.
 van Leth F, Huisamen CB, Badaro R, et al
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):296-300.
 Abstract
 
First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for
naive patients.
 Manfredi R, Calza L, Chiodo F.
 AIDS. 2004 Nov 19;18(17):2331-3.
 Abstract
 
Clinical, Virologic, and Immunologic Response to Efavirenz-or Protease Inhibitor-Based
Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients With Advanced
HIV Infection (EfaVIP 2 Study).
 The EfaVIP Cohort Study Group.
J Acquir Immune Defic Syndr. 2004 Apr 20;35(4):343-350.
 Abstract
 
Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label
Observational Study.
 Manfredi R, Calza L, Chiodo F. 
J Acquir Immune Defic Syndr. 2004 Mar 15;35(5):492-502.
 Abstract